Publication: 4275

Publication: 4275

Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer.

DOI

URL

Google Scholar

Citation:: J Clin Oncol vol 24 (16_suppl) 5006

Meeting Instance:: ASCO 2024
Year:: 2024
Type:: Abstract
Sub type:: Oral
Funding:: AFT
Endpoint:: Secondary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epreprint

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: GU
Sec. Committees:

Pharmas:: JNJ
Grants:: AFT

Corr. Author:
Authors:: Ronald C Chen Gina L Mazza Briant F Fruth Han Xiao Joel Picus Mary-Ellen Taplin Tanya Dorff Leonard Appleman Douglas Weckstein Akash Patnaik Alan Bryce Daniel Shevrin James L Mohler Daniel Anderson Arpit Rao Alan Tan Charles J Ryan Scott E Eggener Michael J Morris Rahul Aggarwal

Networks:: CA043, CA824, IL018, KANSAS, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NY016, LAPS-NY158, LAPS-PA015, LAPS-TN008, METROMIN, MN022, NH038, TX041

Study: AFT-19
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: